WGS: Rasio kapitalisasi marang pendapatan GeneDx Holdings

Simbol lan logo merek Sema4 (WGS)

GeneDx Holdings Corp. (WGS) is shielded from international sanctions due to its localization in the US. The company leads in the diagnosis of rare pathologies by sequencing exomes for clinics and families. Process automation and AI optimize genome analysis. The P/S ratio trend demonstrates the market valuation of revenue, where the indicator reaches 3.40, reflecting a balance between technological development and investment demand.

GeneDx Holdings (WGS): Rasio rega marang pendapatan saka 28.04.2023 nganti 16.11.2026

Rincian metrik lan analitis perusahaan genedx.com (WGS)

- rega saiki lan proyeksi nilai saham:
Ringkesan analitik perusahaan:GeneDx, WGS
Produk asil prodhuksi GeneDx Holdings Corp.

The P/S multiple determines the market value of one unit of annual revenue, allowing an investor to assess the degree to which an asset is overbought relative to its actual cash flows. When analyzing the calculated price-to-sales ratio, it should be noted that the high valuation of GeneDx Holdings Corp. (WGS) is justified by its ownership of a unique DNA database and strict CLIA standards, which create significant barriers to entry for competitors.

Perusahaan pesaing

TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio rega marang dodolan RARE (Ultragenyx)|Kapitalisasi marang pendapatan BEAM|Multiplikator P/S Sarepta Corp|Rasio rega marang pendapatan Twist Bioscience, Inc. (TWST)|Kapitalisasi marang pendapatan 10x Genomics TXG|Rasio rega marang pendapatan Intellia Therapeutics NTLA|Kapitalisasi marang volume dodolan STOK (Stoke Therapeutics, Inc.)|BLFS - Rasio rega marang pendapatan|Rega marang dodolan Wave Pharma|mazetx.com (MAZE) - Rasio rega marang pendapatan|SION - Koefisien rega marang pendapatan|PRME (Prime Medicine Inc) - Multiplikator P/S|Taysha Gene Therapies, Inc. - Rasio rega marang dodolan|Multiplikator P/S QURE|MGTX: Rasio rega marang dodolan|Rasio rega marang pendapatan REGENXBIO RGNX|SLDB: Rasio kapitalisasi marang pendapatan|OCGN: Kapitalisasi marang pendapatan|PACB - Multiplikator P/S|BNTC (Benitec Corp) - Kapitalisasi marang pendapatan|Multiplikator rega marang pendapatan Design Corp DSGN|Rasio rega marang pendapatan Rocket Pharmaceuticals|Multiplikator P/S 4D Molecular Therapeutics, Inc.|Rasio rega marang pendapatan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EDIT (Editas Medicine, Inc.)|Multiplikator P/S Silence Therapeutics Corp SLN|PRQR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Codexis Inc CDXS|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan metagenomi.co|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan